Perceptive Informatics Survey Reveals Industry’s View of Most Valuable EDC-Related Technology Advances

BOSTON, Aug. 5 /PRNewswire-FirstCall/ -- Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (Nasdaq: PRXL), today announced the results of a survey conducted during its recent webinar entitled “Using Advanced Functionality of EDC to Simplify Workflow.”  Perceptive polled biopharmaceutical industry professionals across a broad range of clinical and IT functions about the value of technological advances related to the increased use of Electronic Data Capture (EDC) in clinical development.

Survey results revealed the majority of respondents (66%) believe that the most valuable technological advance related to EDC is the convergence of systems to minimize redundant data entry at sites.  A smaller group of respondents (26%) cited the value of dashboard reports available through EDC to enable greater visibility into trial performance metric data.  Other EDC-related advances noted by survey participants included single sign-on for systems used at sites and web-enabled designer tools to facilitate collaboration.

According to Bill Byrom, Ph.D., Senior Director, Product Strategy, Perceptive Informatics, “From a clinical site user’s perspective, the EDC system represents the primary solution that performs patient-related tasks such as data collection. In studies using more than one technology, a user may need to log into other solutions to perform related activities.  While data integration can eliminate a level of inefficiency and duplication between systems, there is still a need to log in and out of different applications within a single clinical trial.  Our survey results indicate that site users benefit from a more streamlined approach to simplify their workflow.  Product convergence, which is changing the way technologies can be used together, makes the clinical trial process more efficient by allowing the functionality that exists in one application to be accessed through another."

The webinar examined how EDC systems are advancing to include new features that enable sponsors to rapidly collect cleaner clinical data and reduce training costs.  The benefits of converging Randomization and Trial Supply Management (RTSM) technologies with EDC systems to streamline workflow and the value of integrating real-time ePRO data with EDC systems were discussed, as well as the utility of dashboards to view overall study performance.

To access the webcast on demand visit:  http://www.perceptive.com/News/Webinars.  For more information about the Perceptive DataLabs® EDC solution, one of the industry’s first systems to unify the functionality of paper data entry with the flexibility of EDC into one electronic clinical data management platform, visit:  http://www.perceptive.com/EDC.  For more information about Perceptive’s eClinical Suite visit:  http://www.perceptive.com/Solutions/eClinical-Suite.html.

About Perceptive Informatics

Perceptive Informatics, a leading eClinical solutions provider and subsidiary of PAREXEL, is focused on helping customers to accelerate the product development process through innovation. The Perceptive Informatics industry-leading eClinical product portfolio is built on advanced technology that benefits from extensive medical and clinical expertise as well as a deep understanding of the regulatory environment. The portfolio includes Randomization and Trial Supply Management (RTSM) technologies, Medical Imaging, Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), and Electronic Patient-Reported Outcomes (ePRO). For more information about the integrated solutions in Perceptive’s eClinical Suite visit: www.perceptive.com.

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 54 countries around the world, and has approximately 9,500 employees. For more information about PAREXEL International visit www.PAREXEL.com.

This release contains “forward-looking” statements regarding future results and events.  For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “targets,” and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated restructuring charge of approximately $24 million over the second, third, and fourth quarters of Fiscal Year 2010; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.  Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2010 as filed with the SEC on May 7, 2010 which “Risk Factors” discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

SOURCE PAREXEL International Corporation

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED